Why Alterity Therapeutics Limited’s (ATHE) Stock Is Down 5.34%
As of Thursday, October 15, Alterity Therapeutics Limited’s ATHE share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Commentary & Analysis
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Down 6.02%
As of Thursday, October 08, Alterity Therapeutics Limited’s ATHE share price has dipped by 6.02%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Up 6.21%
As of Tuesday, October 06, Alterity Therapeutics Limited’s ATHE share price has surged by 6.21%, which has investors questioning if this is right time to sell.Michael Rose
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Down 10.14%
As of Monday, October 05, Alterity Therapeutics Limited’s ATHE share price has dipped by 10.14%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Alterity Therapeutics Limited’s (ATHE) Stock Is Down 6.88%
As of Friday, October 02, Alterity Therapeutics Limited’s ATHE share price has dipped by 6.88%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $38.4 | $219.1 | 15% |
|
| Shares Out (Mil) | 150.4 | 53.4 | 70% |
|
| Institutional Ownership | 91.5% | 92.9% | 60% |
|
| Float (Mil) | 181.5 | 41.4 | 72% |
|
| Beta | -0.04 | 0.95 | 5% |
|
| Avg Daily Volume (000s) | 413 | 455 | 56% |
|
| Price Change (52-week) |
(41.3%) | 46.6% | 24% |
|
| Growth | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (5.4%) | 13.2% | 9% |
|
| Net Income (5yr) | (7.1%) | (10.1%) | 32% |
|
| EPS (5yr) | 25.6% | 15.8% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (48.6%) | (15.7%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($16) | ($44) | 25% |
|
| EPS (TTM) | ($0.077) | ($1.600) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($33) | 17% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $1 | 49% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $50 | $174 | 16% |
|
| Valuation | ATHE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.64 | 2.11 | 95% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ATHE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 92.7% | 66.0% | 94% |
|
| Net Margin | (648.2%) | (70.6%) | 1% |
|
| ROA | (52.2%) | (47.0%) | 11% |
|
| ROE | (56.4%) | (52.2%) | 14% |
|
| Liabilities to Assets | 7.2% | 29.6% | 4% |
|
| F-Score | 3 | 2 | 18% |
|
Alterity Therapeutics Limited did not pass any screens on 11/3/2026.
